端粒酶逆转录酶基因突变在胶质瘤诊疗中的价值及研究进展
The Value and Research Progress of Telomerase Reverse Transcriptase Gene Mutations in the Diagnosis and Treatment of Gliomas
DOI: 10.12677/acm.2025.1572165, PDF,   
作者: 古丽米热·依力哈木, 王 俭*：新疆医科大学第一附属医院影像中心，新疆 乌鲁木齐
关键词: 胶质瘤；端粒酶逆转录酶；基因；突变；Glioma； Telomerase Reverse Transcriptase； Gene； Mutation
摘要: 胶质瘤(Glioma)作为最常见且侵袭性强的原发性脑肿瘤，因其发病机制复杂，治疗极具挑战，严重威胁人类健康。端粒酶逆转录酶(telomerase reverse transcriptase, TERT)在维持端粒长度中起关键作用，与胶质瘤肿瘤细胞的无限增殖密切相关。近年来，随着TERT在胶质瘤的发生、发展、影像诊断、预后评估及治疗等方面的研究不断深入，为胶质瘤的精准诊疗提供了新的方向和思路。本文就TERT基因突变与胶质瘤的关系，以及调控TERT基因突变在胶质瘤诊疗中的价值及研究进展进行综述。
Abstract: Glioma, as the most common and highly invasive primary brain tumor, poses a significant threat to human health due to its complex pathogenesis and the considerable challenges it presents for treatment. Telomerase reverse transcriptase (TERT) plays a critical role in maintaining telomere length and is closely associated with the unlimited proliferation of tumor cells. In recent years, with the continuous deepening of research on TERT in glioma occurrence, progression, imaging diagnosis, prognosis assessment, and treatment, new directions and insights have been provided for the precise diagnosis and treatment of glioma. This review focuses on the relationship between TERT gene mutations and glioma, as well as the value and research progress of regulating TERT gene mutations in the diagnosis and treatment of glioma.
文章引用：古丽米热·依力哈木, 王俭. 端粒酶逆转录酶基因突变在胶质瘤诊疗中的价值及研究进展[J]. 临床医学进展, 2025, 15(7): 1618-1625. https://doi.org/10.12677/acm.2025.1572165

参考文献

[1] Miller, K.D., Ostrom, Q.T., Kruchko, C., Patil, N., Tihan, T., Cioffi, G., et al. (2021) Brain and Other Central Nervous System Tumor Statistics, 2021. CA: A Cancer Journal for Clinicians, 71, 381-406. [Google Scholar] [CrossRef] [PubMed]
[2] Ferrari, A.J., Santomauro, D.F., Aali, A., Abate, Y.H., Abbafati, C., Abbastabar, H., et al. (2024) Global Incidence, Prevalence, Years Lived with Disability (YLDs), Disability-Adjusted Life-Years (DALYs), and Healthy Life Expectancy (HALE) for 371 Diseases and Injuries in 204 Countries and Territories and 811 Subnational Locations, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021. The Lancet, 403, 2133-2161. [Google Scholar] [CrossRef] [PubMed]
[3] Ostrom, Q.T., Price, M., Neff, C., Cioffi, G., Waite, K.A., Kruchko, C., et al. (2023) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020. Neuro-Oncology, 25, iv1-iv99. [Google Scholar] [CrossRef] [PubMed]
[4] Kannan, S., Murugan, A.K., Balasubramanian, S., Munirajan, A.K. and Alzahrani, A.S. (2022) Gliomas: Genetic Alterations, Mechanisms of Metastasis, Recurrence, Drug Resistance, and Recent Trends in Molecular Therapeutic Options. Biochemical Pharmacology, 201, Article ID: 115090. [Google Scholar] [CrossRef] [PubMed]
[5] Huang, D., Wang, Z., He, X., Diplas, B.H., Yang, R., Killela, P.J., et al. (2015) Recurrent TERT Promoter Mutations Identified in a Large-Scale Study of Multiple Tumour Types Are Associated with Increased TERT Expression and Telomerase Activation. European Journal of Cancer, 51, 969-976. [Google Scholar] [CrossRef] [PubMed]
[6] Palsgrove, D.N., Taheri, D., Springer, S.U., Cowan, M., Guner, G., Mendoza Rodriguez, M.A., et al. (2019) Targeted Sequencing of Plasmacytoid Urothelial Carcinoma Reveals Frequent TERT Promoter Mutations. Human Pathology, 85, 1-9. [Google Scholar] [CrossRef] [PubMed]
[7] Di Nunno, V., Aprile, M., Bartolini, S., Gatto, L., Tosoni, A., Ranieri, L., et al. (2023) The Biological and Clinical Role of the Telomerase Reverse Transcriptase Gene in Glioblastoma: A Potential Therapeutic Target? Cells, 13, Article No. 44. [Google Scholar] [CrossRef] [PubMed]
[8] He, Y., Jiang, K., Liu, B., Meng, H. and Li, Z. (2024) Spatiotemporal Control of Dnazyme Activity for Fluorescent Imaging of Telomerase RNA in Living Cells. Analytica Chimica Acta, 1287, Article ID: 342085. [Google Scholar] [CrossRef] [PubMed]
[9] Perevalova, A.M., Gulyaeva, L.F. and Pustylnyak, V.O. (2024) Roles of Interferon Regulatory Factor 1 in Tumor Progression and Regression: Two Sides of a Coin. International Journal of Molecular Sciences, 25, Article No. 2153. [Google Scholar] [CrossRef] [PubMed]
[10] Yang, Z. and Zhang, X. (2024) The Clinical and Molecular Landscape of Rosette-Forming Glioneuronal Tumors. Biomedicines, 12, Article No. 2325. [Google Scholar] [CrossRef] [PubMed]
[11] 魏志敏, 李子帅, 刘文斌, 等. 端粒酶反转录酶在肿瘤发生和发展中的作用机制[J]. 肿瘤, 2023, 43(5): 448-456.
[12] 郭晓强, 黄卫人, 蔡志明, 等. 端粒酶基因突变与癌症发生[J]. 科学通报, 2015, 60(28): 2790-2793.
[13] Pennisi, G., Bruzzaniti, P., Burattini, B., Piaser Guerrato, G., Della Pepa, G.M., Sturiale, C.L., et al. (2024) Advancements in Telomerase-Targeted Therapies for Glioblastoma: A Systematic Review. International Journal of Molecular Sciences, 25, Article No. 8700. [Google Scholar] [CrossRef] [PubMed]
[14] Walsh, K.M., Wiencke, J.K., Lachance, D.H., Wiemels, J.L., Molinaro, A.M., Eckel-Passow, J.E., et al. (2015) Telomere Maintenance and the Etiology of Adult Glioma. Neuro-Oncology, 17, 1445-1452. [Google Scholar] [CrossRef] [PubMed]
[15] 加潇坤, 彭冲奇, 赵振宇, 等. 脑胶质瘤WHO中枢神经系统肿瘤分类(第五版)分析: 附60例报告[J]. 中国现代神经疾病杂志, 2022, 22(12): 1086-1093.
[16] Powter, B., Jeffreys, S.A., Sareen, H., Cooper, A., Brungs, D., Po, J., et al. (2021) Human TERT Promoter Mutations as a Prognostic Biomarker in Glioma. Journal of Cancer Research and Clinical Oncology, 147, 1007-1017. [Google Scholar] [CrossRef] [PubMed]
[17] Ozair, A., Bhat, V., Alisch, R.S., Khosla, A.A., Kotecha, R.R., Odia, Y., et al. (2023) DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets. Cancers, 15, Article No. 1342. [Google Scholar] [CrossRef] [PubMed]
[18] Heidenreich, B. and Kumar, R. (2017) TERT Promoter Mutations in Telomere Biology. Mutation Research/Reviews in Mutation Research, 771, 15-31. [Google Scholar] [CrossRef] [PubMed]
[19] 郑义, 宋莱荣, 徐晓颖, 等. 人胶质母细胞瘤细胞系Y1203的构建及应用[J]. 首都医科大学学报, 2023, 44(5): 733-740.
[20] 张科平, 许洁, 林丹义, 等. TERT启动子突变检测在胶质瘤中的意义[J]. 诊断病理学杂志, 2022, 29(7): 628-630, 634.
[21] Vinagre, J., Pinto, V., Celestino, R., Reis, M., Pópulo, H., Boaventura, P., et al. (2014) Telomerase Promoter Mutations in Cancer: An Emerging Molecular Biomarker? Virchows Archiv, 465, 119-133. [Google Scholar] [CrossRef] [PubMed]
[22] Shalaby, T., Hiyama, E. and Grotzer, M.A. (2010) Telomere Maintenance as Therapeutic Target in Embryonal Tumours. Anti-Cancer Agents in Medicinal Chemistry, 10, 196-212. [Google Scholar] [CrossRef] [PubMed]
[23] Yong, V.W., Power, C., Forsyth, P. and Edwards, D.R. (2001) Metalloproteinases in Biology and Pathology of the Nervous System. Nature Reviews Neuroscience, 2, 502-511. [Google Scholar] [CrossRef] [PubMed]
[24] 国家卫生健康委员会医政医管局, 中国抗癌协会脑胶质瘤专业委员会, 中国医师协会脑胶质瘤专业委员会. 脑胶质瘤诊疗指南(2022版) [J]. 中华神经外科杂志, 2022, 38(8): 757-777.
[25] Rodriguez, F.J., Vizcaino, M.A. and Lin, M. (2016) Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults. The Journal of Molecular Diagnostics, 18, 620-634. [Google Scholar] [CrossRef] [PubMed]
[26] Rudà, R., Pellerino, A. and Soffietti, R. (2024) Blood and Cerebrospinal Fluid Biomarkers in Neuro-Oncology. Current Opinion in Neurology, 37, 693-701. [Google Scholar] [CrossRef] [PubMed]
[27] Vuong, H.G., Altibi, A.M.A., Duong, U.N.P., Ngo, H.T.T., Pham, T.Q., Chan, A.K., et al. (2017) TERT Promoter Mutation and Its Interaction with IDH Mutations in Glioma: Combined TERT Promoter and IDH Mutations Stratifies Lower-Grade Glioma into Distinct Survival Subgroups—A Meta-Analysis of Aggregate Data. Critical Reviews in Oncology/Hematology, 120, 1-9. [Google Scholar] [CrossRef] [PubMed]
[28] Singh, G., Singh, A., Bae, J., Manjila, S., Spektor, V., Prasanna, P., et al. (2024) New Frontiers in Domain-Inspired Radiomics and Radiogenomics: Increasing Role of Molecular Diagnostics in CNS Tumor Classification and Grading Following WHO CNS-5 Updates. Cancer Imaging, 24, Article No. 133. [Google Scholar] [CrossRef] [PubMed]
[29] Mo, Z., Xin, J., Chai, R., Woo, P.Y.M., Chan, D.T.M. and Wang, J. (2022) Epidemiological Characteristics and Genetic Alterations in Adult Diffuse Glioma in East Asian Populations. Cancer Biology & Medicine, 19, 1440-1459. [Google Scholar] [CrossRef] [PubMed]
[30] Barritault, M., Meyronet, D. and Ducray, F. (2018) Molecular Classification of Adult Gliomas: Recent Advances and Future Perspectives. Current Opinion in Oncology, 30, 375-382. [Google Scholar] [CrossRef] [PubMed]
[31] Menyhárt, O. and Győrffy, B. (2019) Principles of Tumorigenesis and Emerging Molecular Drivers of SHH‐Activated Medulloblastomas. Annals of Clinical and Translational Neurology, 6, 990-1005. [Google Scholar] [CrossRef] [PubMed]
[32] Appin, C.L. and Brat, D.J. (2015) Biomarker-Driven Diagnosis of Diffuse Gliomas. Molecular Aspects of Medicine, 45, 87-96. [Google Scholar] [CrossRef] [PubMed]
[33] Brandner, S. and von Deimling, A. (2015) Diagnostic, Prognostic and Predictive Relevance of Molecular Markers in Gliomas. Neuropathology and Applied Neurobiology, 41, 694-720. [Google Scholar] [CrossRef] [PubMed]
[34] Wu, L., Fidan, K., Um, J. and Ahn, K.S. (2020) Telomerase: Key Regulator of Inflammation and Cancer. Pharmacological Research, 155, Article ID: 104726. [Google Scholar] [CrossRef] [PubMed]
[35] 王雷明, 王玮, 刘莉, 等. 成人IDH野生型弥漫性胶质瘤的临床病理学及分子遗传学特征[J]. 中华病理学杂志, 2021, 50(7): 734-739.

为你推荐